By using our transgenic model, we found that three doses of anti-Tat Abs reduced KS-like lesion severity developing in IC-treated BKV/Tat transgenic mice when anti-Tat Abs were administered at an early-stage of lesion development. This evidence concerns the gene TAT and Kaposi's sarcoma.